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Abstract
A 52 year old female presented with a Siewert's type III gastroesophageal junction (GEJ) adenocarcinoma treated
with neoadjuvant chemotherapy, laparoscopic-robotic total gastrectomy, and adjuvant chemoradiation.
Keywords: Gastroesophageal junction; Laparoscopic gastrectomy
Abbreviations:
GEJ: Gastroesophageal Junction; FISH: Fluorescence In Situ
Hybridization; CT: Computed Tomography; PET: Positron Emission
Tomography; EUS: Endoscopic Ultrasound
Case Description
A 52 year old female presented with a Siewert’s type III
gastroesophageal junction (GEJ) adenocarcinoma treated with
neoadjuvant chemotherapy, laparoscopic-robotic total gastrectomy,
and adjuvant chemoradiation. Presenting symptoms were a 6 week
history of worsening belching and abdominal bloating.
 The patient was first evaluated by gastroenterology and underwent
upper endoscopy with findings significant for a 1 cm nodule at the GEJ
with thickening of the gastric cardia and associated erosions.  
Biopsies were taken of the gastric body and antrum, and the nodule.
Biopsies of the body and antrum returned as benign. Biopsy of the
nodule returned as well-differentiated adenocarcinoma, HER2/neu
was positive by fluorescence in situ hybridization (FISH).  Computed
tomography (CT) scans of the chest, abdomen, and pelvis revealed
mild gastric wall thickening without evidence of metastatic disease.
Positron emission tomography (PET) scan identified two areas of
hypermetabolic foci along the greater curvature of the stomach in
addition to activity at the GEJ without evidence of metastatic disease
(Figure 1A and B).
Endoscopic ultrasound (EUS) and diagnostic laparoscopy were
performed. EUS revealed invasion into the adventitia of the cardia
without evidence of surrounding adenopathy, staging T3N0.
Diagnostic laparoscopy and port placement were completed
concurrently.
At the time of surgery, the stomach was found to be edematous at
the cardia and fundus including the area of the lesser curvature with
concern for linitis plastica extending into the distal esophagus (Figure
2). There was no evidence of peritoneal disease at the time of
laparoscopy.
Additionally, genetic testing was performed as part of her initial
work up and evaluation secondary to her family history of breast and
rectal cancer with no clinically significant mutations identified.
Figure 1: Preoperative PET scan. Preoperative PET scan with area of
hypermetabolism along the greater curvature of the stomach as
noted by the white arrow.
Figure 2: Diagnostic laparoscopy. Laparoscopic image taken at the
time of diagnostic laparoscopy. L: Liver, S: Stomach, arrow denotes
area along the lesser curvature which appeared thickened and
injected with concern for linitis plastica-type change.
She received 6 cycles of neoadjuvant chemotherapy with mDCF and
trastuzumab [1]. Four weeks after the completion of her neoadjuvant
therapy, she underwent a laparoscopic, robotic-assisted total
gastrectomy with roux-en-Y esophagojejunostomy, D2
lymphadenectomy and jejunostomy tube placement.  The majority of
the dissection was completed robotically and the anastomosis was
Bourgon et al., J Gastrointest Dig Syst 2015, 5:6 
DOI: 10.4172/2161-069X.1000369
Case Report Open Access
J Gastrointest Dig Syst
ISSN:2161-069X JGDS, an open access journal












Journal of Gastrointestinal &
Digestive System
hand-sewn using the robot (Figure 3). Pathology revealed grade 3,
poorly-differentiated adenocarcinoma centered at the cardia and
extending to the GEJ and fundus, surgical margins were negative, 6/16
lymph nodes were positive, and HER2/neu was negative. Final staging
was ypT3N2, Stage IIIB. Final pathology did not reveal any evidence of
chemotherapy response with all viable tumor noted. The postoperative
course was complicated by a slow return to oral intake. Tube feeds were
continued for 8 weeks postoperatively following which the jejunostomy
tube was removed. Secondary to the poor pathologic response to
neoadjuvant chemotherapy, it was decided to treat postoperatively with
5-fluorouracal-based chemoradiation (4500 cGy over 5 weeks) as per
McDonald protocol, which she completed without further delay [2].
Figure 3: Robotic hand-sewn esophagojejunal anastomosis. Hand-
sewn robotic-assisted esophageal to jejunal anastomosis. L: Liver, E:
Proximal esophageal margin, J: Jejunum.
Ten months postoperatively the patient developed difficulty with
oral intake and was admitted to the hospital several times for presumed
partial small bowel obstruction. Ultimately, parenteral nutrition was
initiated. CT scanning of the abdomen and pelvis revealed dilated
small bowel loops in the epigastrium, bilateral hydronephrosis and
ascites.  Diagnostic laparoscopy was performed and revealed diffuse
peritoneal disease. Biopsy confirmed metastatic adenocarcinoma.
Jejunostomy tube was replaced. After multidisciplinary discussion, the
patient elected to enroll in Hospice and succumbed to her disease
shortly thereafter.  
Discussion
The described case represented an unfortunate circumstance of
locally advanced gastric cancer progressing to metastatic disease
despite best medical therapy. It highlights the complex presentation of
gastric cancer patients and the importance of multidisciplinary
discussion in their management.
The classification of GEJ cancers was first described by Siewert in
2000 [3]. The classification system allows for uniform description of
these tumors in addition to guiding recommended surgical therapies.
Classically, type I tumors are recommended for esophagectomy and
type III tumors are recommended for total gastrectomy [4]. Type II
tumors can be treated with either surgical approach with the goal to
obtain adequate lymphadenectomy and negative surgical margins. In
their original series, postoperative mortality was higher for the
esophagectomy group suggesting a preference for gastrectomy when
technically feasible [3].
There remains some debate in the published literature regarding the
management of Siewert’s type III GEJ tumors. Type III tumors are
known to be larger at presentation and more infiltrative when
compared to type II tumors [5,6]. The median 5 year survival for type
III tumors is 51-63% [7-9]. In a 2007 series by Barbour et al. 52% of
patients with type III tumors were treated with gastrectomy with
limited esophagectomy while the remaining type III patients were
treated with extended esophagectomy.[10] The median esophageal
margin length was 2.5 cm for type III tumors compared to 3.5 cm for
type 1 and 4.0 for type II. Margin length of >3.8 cm was found to be an
independent predictor of overall survival, similar to the number of
positive nodes, AJCC T classification, and poorly differentiated
tumors. Margins were not predictive of survival in patients with
greater than 6 positive lymph nodes.[10] Similar studies have
supported wide margin resection [11]. However, in a 2015 series from
the US Gastric Cancer Collaborative, the importance of gastric cancer
resection margins was re-examined. Proximal margin length was not
found to be predictive of increased local recurrence or overall survival.
Further, while R1 resection was associated with increased nodal
disease burden, it was not found to be associated with increased local
recurrence or decreased overall survival. The recommendations of this
series were to limit wide margin resection, particularly if it required
extended esophageal resection [12].
Kneuertz et al. evaluated the type of surgery for Siewert’s type II and
III tumors in relation to overall survival [7]. The majority of patients in
this study presented with locally advanced disease and were treated
neoadjuvantly with chemoradiation. Seventy-five percent of patients
with type II tumors were treated with esophagectomy, while 88% of
patients with type III tumors were treated with gastrectomy. The type
of surgery was not found to be predictive of R0 resection rates or
overall survival. The only factor found to be associated with improved
overall survival was extended lymphadenectomy. Similar results were
previously reported by Barbour et al. in 2007 with adequate staging, as
defined by >/= 15 lymph nodes, in T2 or greater tumors to be an
independent prognostic factor of improved survival [13].
Siewert’s type II/III tumors have been shown to have a better
response to neoadjuvant chemoradiation with increased rates of
complete pathologic response. However, while there was no individual
differences between the classifications, when Siewert’s type I tumors
are compared to II/III tumors, type II/III tumors are found to have an
overall increased rate of local recurrence [14]. Patterns of recurrence
have been shown to differ between the groups with disseminated
recurrence being the most common for Siewert’s type III lesions [15].
In this case we utilized a minimally invasive approach with both
laparoscopic and robotic resection. Several studies have demonstrated
the safety and oncologic efficacy of minimally invasive resection for
advanced gastric cancer [16-18]. In a recent meta-analysis comparing
open verses minimally invasive laparoscopic total gastrectomy,
minimally invasive total gastrectomy was found to have equivalent
lymph node yield and mortality with shorter time to first flatus,
decreased hospital stay, and fewer complications [16]. The data for
robotic gastric cancer resections is still evolving. However, it has been
shown to be equivalent to laparoscopic resections with increased
operative time but lower intraoperative blood loss and improved
lymph node retrieval [19].
Conclusion
In conclusion, the current literature would support that the type
of surgery selected is not an independent predictor of outcome. But
rather, the adequacy of oncologic resection focusing on R0 resection
and, more importantly, adequate lymphadenectomy appear to improve
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patient outcome. As this case demonstrates, despite best surgical
management including negative-margin resection and extended
lymphadenectomy, gastroesophageal junction adenocarcinoma
remains an aggressive disease with increased rates of local and distant
recurrence.
References
1. Keskin S, Yaldaz I, Sen F, Aydogan F, Kilic L, et al. (2013) Modified DCF
(mDCF) regimen seems to be as effective as original DCF in advanced
gastric cancer (AGC). Clin Transl Oncol 15: 403-408.
2. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, et al.
(2001) Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl J
Med 345: 725-730.
3. Rüdiger Siewert J, Feith M, Werner M, Stein HJ (2000) Adenocarcinoma
of the esophagogastric junction: results of surgical therapy based on
anatomical/topographic classification in 1,002 consecutive patients. Ann
Surg 232: 353-361.
4. Goto H, Tokunaga M, Miki Y, Makuuchi R, Sugisawa N, et al. (2014) The
optimal extent of lymph node dissection for adenocarcinoma of the
esophagogastric junction differs between Siewert type II and Siewert type
III patients. Gastric Cancer .
5. Zhang WH, Chen XZ, Liu K, Anil K, Yang K, et al. (2014) Comparison of
the clinicopathological characteristics and the survival outcomes between
the Siewert type II/III adenocarcinomas. Med Oncol 31: 116.
6. Curtis NJ, Noble F, Bailey IS, Kelly JJ, Byrne JP, et al. (2014) The relevance
of the Siewert classification in the era of multimodal therapy for
adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol 109:
202-207.
7. Kneuertz PJ, Hofstetter WL, Chiang YJ, Das P, Blum M, et al. (2015)
Long-Term Survival in Patients with Gastroesophageal Junction Cancer
Treated with Preoperative Therapy: Do Thoracic and Abdominal
Approaches Differ? Ann Surg Oncol .
8. Hosokawa Y, Kinoshita T, Konishi M (2012) Clinicopathological features
and prognostic factors of adenocarcinoma of the esophagogastric
junction according to Siewert classification: experiences at a single
institution in Japan. Ann Surg Oncol 19: 677-683.
9. Fang WL, Wu CW, Chen JH, Lo SS, Hsieh MC, et al. (2009)
Esophagogastric junction adenocarcinoma according to Siewert
classification in Taiwan. Ann Surg Oncol 16: 3237-3244.
10. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, et al. (2007)
Adenocarcinoma of the gastroesophageal junction: influence of
esophageal resection margin and operative approach on outcome. Ann
Surg 246: 1-8.
11. Mine S, Sano T, Hiki N, Yamada K, Kosuga T, et al. (2013) Proximal
margin length with transhiatal gastrectomy for Siewert type II and III
adenocarcinomas of the oesophagogastric junction. Br J Surg 100:
1050-1054.
12. Postlewait LM, Squires MH, Kooby DA (2015) The importance of the
proximal resection margin distance for proximal gastric adenocarcinoma:
A multi-institutional study of the US Gastric Cancer Collaborative. J Surg
Oncol 112: 203-207.
13. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, et al. (2007)
Lymphadenectomy for adenocarcinoma of the gastroesophageal junction
(GEJ): impact of adequate staging on outcome. Ann Surg Oncol 14:
306-316.
14. Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, et al. (2015)
Impact of the Siewert Classification on the Outcome of Patients Treated
by Preoperative Chemoradiotherapy for a Nonmetastatic
Adenocarcinoma of the Oesophagogastric Junction. Gastroenterol Res
Pract 2015: 404203.
15. Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, et al.
(2014) Recurrence patterns of esophagogastric junction adenocarcinoma
according to Siewert's classification after radical resection. Anticancer Res
34: 4391-4397.
16. Straatman J, van der Wielen N, Cuesta MA, de Lange-de Klerk ES, Jansma
EP, et al. (2015) Minimally Invasive Versus Open Total Gastrectomy for
Gastric Cancer: A Systematic Review and Meta-analysis of Short-Term
Outcomes and Completeness of Resection: Surgical Techniques in Gastric
Cancer. World J Surg.
17. Tuttle R, Hochwald SN, Kukar M, Ben-David K (2015) Total laparoscopic
resection for advanced gastric cancer is safe and feasible in the Western
population. Surg Endosc .
18. Kelly KJ, Selby L, Chou JF, Dukleska K, Capanu M, et al. (2015)
Laparoscopic Versus Open Gastrectomy for Gastric Adenocarcinoma in
the West: A Case-Control Study. Ann Surg Oncol 22: 3590-3596.
19. Shen W, Xi H, Wei B, Cui J, Bian S, et al. (2015) Robotic versus
laparoscopic gastrectomy for gastric cancer: comparison of short-term
surgical outcomes. Surg Endosc .
 
Citation: Bourgon AL, Hellan M, Tuttle R (2015) Management of Siewert's Type III Gastroesophageal Junction Adenocarcinoma in a 52 Year Old
Female. J Gastrointest Dig Syst 5: 369. doi:10.4172/2161-069X.1000369
Page 3 of 3
J Gastrointest Dig Syst
ISSN:2161-069X JGDS, an open access journal
Volume 5 • Issue 6 • 1000369
